Status:
UNKNOWN
AMH and Pregnancy Outcome in IVF
Lead Sponsor:
Al Baraka Fertility Hospital
Conditions:
AMH
Eligibility:
FEMALE
22-45 years
Brief Summary
Anti-Mu¨llerian hormone (AMH) is an established marker of ovarian reserve (La Marca et al., 2010; Nelson et al., 2009) and predicts both high and low responses in ovarian stimulation cycles (Eldar-Gev...
Eligibility Criteria
Inclusion
- Women ≥22 years age AMH is 0.5 and less Body mass index- 18.5-30 kg/m 2 The normal uterine cavity on ultrasound scan At least one good quality embryo present for transfer Women willing to comply with the clinical study protocol
Exclusion
- Women ≥ 45 years age
- AMH \>0.5
- Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids, hydrosalpinx, and adenomyosis)
- Endocrine dysfunction or organ dysfunction such as liver or kidney failure.
Key Trial Info
Start Date :
October 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 25 2020
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT04512807
Start Date
October 15 2020
End Date
November 25 2020
Last Update
October 22 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.